CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Table 1 Comparison of baseline clinical characteristics of patients between DEB-TACE and cTACE

Variables	DEB-TACE	cTACE	χ² or t value	p value
Variables	n = 24	n = 30	χ² or t value	p value
Gender (M/F)	22/2	27/3	0.044	0.834^*
Age (mean ± SD)	56.25 ± 7.47	52.83 ± 6.13	0.225	0.823^#
Child-Pugh
A	10 (42%)	14 (47%)	0.135	0.713^*
B	14 (58%)	16 (53%)
BCLC stage
B	13 (54%)	17 (57%)	0.034	0.854^*
C	11 (46%)	13 (43%)
ECOG PS
0 ~ 1	15 (63%)	18 (60%)	0.035	0.851^*
2	9 (37%)	12 (40%)
Etiology
HBV	15 (62.5%)	18 (60.0%)	0.035	0.851^*
HCV	5 (20.8%)	4 (13.3%)	0.540	0.462^*
Alcohol	1 (4.2%)	2 (6.7%)	0.159	0.690^*
Other and mixed	3 (12.5%)	6 (20.0%)	0.540	0.462^*
Amount of tumors
1~2	16 (66.7%)	19 (63.3%)	0.065	0.799^*
3	8 (33.3%)	11 (36.7%)
Tumor diameter mean ± SD (cm)	7.25 ± 2.33	7.53 ± 2.39	−0.438	0.663^#

*χ² test, ^#t test
BCLC Barcelona clinic liver cancer, ECOG PS eastern cooperative oncology group performance status, HBV hepatitis B virus, HCV hepatitis C virus

ISSN: 1477-7819